A team from Brigham and Women’s Hospital are developing a test that can detect tau protein, a calling card for Alzheimer’s disease.
IVD - News
The Menlo Park, CA-based company’s 50,000-patient trial will launch in 2019 and could be one of the most significant events of the year for the liquid biopsy market.
Daxor’s new technology designed to measure blood volume has the potential to reduce patient readmission rates and improve outcomes for patients suffering from acute heart failure.
A startup spawned from Oxford University is trying to commercialize components of a quantum computing technology that could ultimately improve the downstream end of existing diagnostic devices.
The Madison, WI-based company said its test can identify metabolic subtypes associated with the Autism Spectrum and can be used to screen children as young as 18 months.
Diagnostics manufacturer OpGen is partnering with ILUM and the NY State Department of Health to detect, track, and manage antimicrobial-resistant infections at healthcare institutions statewide.
Aromyx Corp. announces its groundbreaking biosensor technology based on the human sense of smell and taste. The company says the new technology has the potential to be used as a diagnostic tool to detect early stage cancer and disease.
Quadrant Biosciences scored a $2 million NIH grant to supports its epigenetic diagnostic test for autism spectrum disorder.
The study looked at nearly 1,048 patients to test the prognostic value of the VeriStrat test in patients with non-small cell lung cancer.
A new diagnostic system with digital imaging capabilities aims to enhance lab capabilities across the globe through multi-test processing, dry slide technology, and a full testing environment for accurate testing in a waterless environment.
FDA has given approval for the Roche’s cobas HPV Test to be used as the first-line screening test for cervical cancer in women 25 and older using cervical specimens collected in SurePath preservative fluid, a collection medium commonly used for Pap tests.